The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Abstract
Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally. Oral fingolimod was approved in September 2010 by the US Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS. In the clinical trials that led to approval, fingolimod reduced not only acute relapses and magnetic resonance imaging lesion activity but also disability progression and brain volume loss, suggesting preservation of tissue. Fingolimod's mechanism of action in MS is not known with certainty. Its active form, fingolimod‐phosphate (fingolimod‐P), is a sphingosine 1‐phosphate receptor (S1PR) modulator that inhibits egress of lymphocytes from lymph nodes and their recirculation, potentially reducing trafficking of pathogenic cells into the central nervous system (CNS). Fingolimod also readily penetrates the CNS, and fingolimod‐P formed in situ may have direct effects on neural cells. Fingolimod potently inhibits the MS animal model, experimental autoimmune encephalomyelitis, but is ineffective in mice with selective deficiency of the S1P 1 S1PR subtype on astrocytes despite normal expression in the immune compartment. These findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti‐inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS. In clinical trials, fingolimod was generally safe and well tolerated. Its interaction with S1PRs in a variety of tissues largely accounts for the reported adverse effects, which were seen more frequently with doses 2.5 to 10× the approved 0.5mg dose. Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies. Ann Neurol 2011;69:759–777
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationSphingosine-1-phosphate: an enigmatic signalling lipid
Spiegel, S., & Milstien, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1103 · Cited by 2,075
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.-X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S.-S., Lee, M.-J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10905 · Cited by 1,149
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients
Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005) · Science · doi:10.1126/science.1113640 · Cited by 787
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Self-citationEssential Role for Sphingosine Kinases in Neural and Vascular Development
Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., & Proia, R. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11113-11121.2005 · Cited by 742
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network
Rosen, H., & Goetzl, E. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1650 · Cited by 694
Sanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M.-Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311743200 · Cited by 626
Self-citationChiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
Self-citationThe immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., Naves, R., Han, M., Zhong, F., Castellanos, J. G., et al. (2010) · Nature Medicine · doi:10.1038/nm.2110 · Cited by 534
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
Allende, M. L., Sasaki, T., Kawai, H., Olivera, A., Mi, Y., van Echten-Deckert, G., Hajdu, R., Rosenbach, M., Keohane, C. A., Mandala, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406512200 · Cited by 447
Brinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Oo, M. L., Thangada, S., Wu, M.-T., Liu, C. H., Macdonald, T. L., Lynch, K. R., Lin, C.-Y., & Hla, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610318200 · Cited by 405
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival
Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M. S., Calver, A. R., Duddy, G., Walsh, F. S., Pangalos, M. N., Arimura, N., Kaibuchi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4645-04.2005 · Cited by 338
Forrest, M., Sun, S.-Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062828 · Cited by 333
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
Miller, D. H., Soon, D., Fernando, K. T., MacManus, D. G., Barker, G. J., Yousry, T. A., Fisher, E., O'Connor, P. W., Phillips, J. T., Polman, C. H., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260064.77700.fd · Cited by 332
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330
Self-citationFoster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127183 · Cited by 322
Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A., & Chun, J. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.507 · Cited by 322
Self-citationCharacterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8
Im, D.-S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G.-J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14281 · Cited by 320
Lo, C. G., Xu, Y., Proia, R. L., & Cyster, J. G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041509 · Cited by 319
Astrocytes in multiple sclerosis: A product of their environment
Nair, A., Frederick, T. J., & Miller, S. D. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8059-5 · Cited by 313
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2
Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S., & Spiegel, S. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01168-2 · Cited by 302
Astrocytes—Friends or foes in multiple sclerosis?
Williams, A., Piaton, G., & Lubetzki, C. (2007) · Glia · doi:10.1002/glia.20546 · Cited by 302
Signaling and biological actions of sphingosine 1-phosphate
Hla, T. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00046-x · Cited by 280
Edsall, L. C., Pirianov, G. G., & Spiegel, S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-06952.1997 · Cited by 275
Postma, F. R., Jalink, K., Hengeveld, T., & Moolenaar, W. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00595.x · Cited by 273
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
Zemann, B., Kinzel, B., Müller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., & Billich, A. (2006) · Blood · doi:10.1182/blood-2005-07-2628 · Cited by 264
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Miron, V. E., Jung, C. G., Kim, H. J., Kennedy, T. E., Soliven, B., & Antel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21227 · Cited by 255
Distribution of lymphocyte subsets and natural killer cells in the human body
Westermann, J., & Pabst, R. (1992) · The Clinical Investigator · doi:10.1007/bf00184787 · Cited by 248
Graeler, M., & Goetzl, E. J. (2002) · The FASEB Journal · doi:10.1096/fj.02-0548com · Cited by 230
Webb, M., Tham, C.-S., Lin, F.-F., Lariosa-Willingham, K., Yu, N., Hale, J., Mandala, S., Chun, J., & Rao, T. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.015 · Cited by 226
Self-citationPlasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism
Kabashima, K., Haynes, N. M., Xu, Y., Nutt, S. L., Allende, M. L., Proia, R. L., & Cyster, J. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061289 · Cited by 220
Kataoka, H., Sugahara, K., Shimano, K., Teshima, K., Koyama, M., Fukunari, A., & Chiba, K. (2005) · PubMed · Cited by 216
Tedesco-Silva, H., Mourad, G., Kahan, B. D., Boira, J. G., Weimar, W., Mulgaonkar, S., Nashan, B., Madsen, S., Charpentier, B., Pellet, P., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000121761.02129.a6 · Cited by 215
Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720
Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O'Neill, S. L., Morris, M. A., Setiady, Y., Zhu, R., Zigler, M. A., Burcin, T. L., Ley, K., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506293200 · Cited by 210
Sorensen, S. D., Nicole, O., Peavy, R. D., Montoya, L. M., Lee, C. J., Murphy, T. J., Traynelis, S. F., & Hepler, J. R. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1199 · Cited by 210
Sphingosine‐1‐phosphate induces proliferation and morphological changes of neural progenitor cells
Harada, J., Foley, M., Moskowitz, M. A., & Waeber, C. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02219.x · Cited by 203
Kimura, A., Ohmori, T., Ohkawa, R., Madoiwa, S., Mimuro, J., Murakami, T., Kobayashi, E., Hoshino, Y., Yatomi, Y., & Sakata, Y. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0223 · Cited by 202
Generation and metabolism of bioactive sphingosine‐1‐phosphate
Stunff, H. L., Milstien, S., & Spiegel, S. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20097 · Cited by 201
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
Mehling, M., Lindberg, R., Raulf, F., Kuhle, J., Hess, C., Kappos, L., & Brinkmann, V. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd64 · Cited by 195
Endothelial cell barrier regulation by sphingosine 1‐phosphate
McVerry, B. J., & Garcia, J. G. N. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20088 · Cited by 191
Enzymatic Measurement of Sphingosine 1-Phosphate
Edsall, L. C., & Spiegel, S. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4157 · Cited by 182
Van Brocklyn, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., & Spiegel, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4626 · Cited by 181
The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors
Coelho, R. P., Payne, S. G., Bittman, R., Spiegel, S., & Sato-Bigbee, C. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123927 · Cited by 175
Pébay, A., Toutant, M., Prémont, J., Calvo, C., Venance, L., Cordier, J., Glowinski, J., & Tencé, M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01585.x · Cited by 171
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
Marsolais, D., & Rosen, H. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2356 · Cited by 167
Activation of sphingosine‐1‐phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration
Novgorodov, A. S., El‐Awani, M., Bielawski, J., Obeid, L. M., & Gudz, T. I. (2007) · The FASEB Journal · doi:10.1096/fj.06-7420com · Cited by 167
Koyrakh, L., Roman, M. I., Brinkmann, V., & Wickman, K. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00754.x · Cited by 166
Dev, K. K., Müllershausen, F., Mattes, H., Kuhn, R. R., Bilbe, G., Hoyer, D., & Mir, A. K. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.005 · Cited by 166
Culmsee, C., Gerling, N., Lehmann, M., Nikolova‐Karakashian, M., Prehn, J. H. M., Mattson, M. P., & Krieglstein, J. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00539-0 · Cited by 165
Central nervous system-directed effects of FTY720 (fingolimod)
Miron, V. E., Schubart, A., & Antel, J. P. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.031 · Cited by 164
Vogel, P., Donoviel, M. S., Read, R., Hansen, G. M., Hazlewood, J., Anderson, S. J., Sun, W., Swaffield, J., & Oravecz, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004112 · Cited by 159
Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells
Jung, C., Kim, H., Miron, V. E., Cook, S. P., Kennedy, T. E., Foster, C. A., Antel, J. P., & Soliven, B. C. (2007) · Glia · doi:10.1002/glia.20576 · Cited by 158
Balatoni, B., Storch, M. K., Swoboda, E.-M., Schönborn, V., Koziel, A., Lambrou, G. N., Hiestand, P. C., Weissert, R., & Foster, C. A. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.06.023 · Cited by 158
Involvement of Sphingosine-1-Phosphate in Glutamate Secretion in Hippocampal Neurons
Kajimoto, T., Okada, T., Yu, H., Goparaju, S. K., Jahangeer, S. M., & Nakamura, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01465-06 · Cited by 149
Salvadori, M., Budde, K., Charpentier, B., Klempnauer, J. L., Nashan, B., Pallardó, L., Eris, J., Schena, F. P., Eisenberger, U., Rostaing, L. P. E., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01552.x · Cited by 145
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors
Müllershausen, F., Craveiro, L. M., Shin, Y., Cortés-Cros, M., Bassilana, F., Osinde, M., Wishart, W. L., Guerini, D., Thallmair, M., Schwab, M. E., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04629.x · Cited by 142
The roles of ceramide and complex sphingolipids in neuronal cell function
Buccoliero, R., & Futerman, A. H. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00049-5 · Cited by 131
Fingolimod and Sphingosine-1-Phosphate — Modifiers of Lymphocyte Migration
Maßberg, S., & von Andrian, U. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068159 · Cited by 129
Kahan, B. D., Karlix, J. L., Ferguson, R. M., Leichtman, A. B., Mulgaonkar, S. P., Gonwa, T. A., Skerjanec, A., Schmouder, R., & Chodoff, L. (2003) · Transplantation · doi:10.1097/01.tp.0000084822.01372.ac · Cited by 127
Sphingosine-1-phosphate signaling in the cardiovascular system
Peters, S. L. M., & Alewijnse, A. E. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.09.008 · Cited by 125
Yu, N., Lariosa-Willingham, K. D., Lin, F., Webb, M., & Rao, T. S. (2003) · Glia · doi:10.1002/glia.10297 · Cited by 124
Bassi, R., Anelli, V., Giussani, P., Tettamanti, G., Viani, P., & Riboni, L. (2006) · Glia · doi:10.1002/glia.20324 · Cited by 123
Tölle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schönfelder, G., Schäfers, M. A., Lipinski, K. V. W., Jankowski, J., Jankowski, V., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000164321.91452.00 · Cited by 122
Self-citationCell Type-specific Localization of Human Cardiac S1P Receptors
Mazurais, D., Robert, P., Gout, B., Berrebi‐Bertrand, I., Laville, M.-P., & Calmels, T. (2002) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540205000507 · Cited by 120
S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate
Salomone, S., Yoshimura, S.-I., Reuter, U., Foley, M., Thomas, S. S., Moskowitz, M. A., & Waeber, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01731-x · Cited by 119
Xie, J., Nomura, N., Koprak, S., Quackenbush, E. J., Forrest, M. J., & Rosen, H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3662 · Cited by 116
YANAGAWA, Masubuchi, & Chiba (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00639.x · Cited by 115
FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects
Schmouder, R., Serra, D. B., Wang, Y., Kovarik, J. M., Dimarco, J., Hunt, T. L., & Bastien, M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289853 · Cited by 110
Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation
Junior, H. T. S., Pescovitz, M. D., Cibrik, D. M., Rees, M. A., Mulgaonkar, S. P., Kahan, B. D., Gugliuzza, K., Rajagopalan, P. R., Esmeraldo, R. D. M., Lord, H., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000251718.95622.b3 · Cited by 108
Anelli, V., Bassi, R., Tettamanti, G., Viani, P., & Riboni, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02955.x · Cited by 107
McGiffert, C., Contos, J. J. A., Friedman, B., & Chun, J. J. M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03404-x · Cited by 106
Self-citationRate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a
Hardmeier, M., Wagenpfeil, S., Freitag, P., Fisher, E., Rudick, R. A., Kooijmans, M., Clanet, M., Radue, E. W., & Kappos, L. (2005) · Neurology · doi:10.1212/01.wnl.0000149516.30155.b8 · Cited by 104
Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS
Terai, K., Soga, T., Takahashi, M. P., Kamohara, M., Ohno, K., Yatsugi, S., Okada, M., & Yamaguchi, T. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00791-1 · Cited by 102
Budde, K., Schmouder, R., Nashan, B., Brunkhorst, R. R., Lücker, P. W., Mayer, T., Brookman, L. J., Nedelman, J. R., Skerjanec, A., Böhler, T., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00130.x · Cited by 102
Rius, R. A., Edsall, L. C., & Spiegel, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01277-5 · Cited by 98
Basic Fibroblast Growth Factor-induced Proliferation of Primary Astrocytes
Riboni, L., Viani, P., Bassi, R., Giussani, P., & Tettamanti, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011570200 · Cited by 97
Sphingosine-1-Phosphate/Sphingosine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness
Roviezzo, F., Lorenzo, A. D., Bucci, M., Brancaleone, V., Vellecco, V., Nardo, M. D., Orlotti, D., Palma, R. D., Rossi, F., D’Agostino, B., et al. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0383oc · Cited by 97
Wu, Y., Mizugishi, K., Bektas, M., Sandhoff, R., & Proia, R. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn126 · Cited by 97
Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod
Miron, V. E., Hall, J. A., Kennedy, T. E., Soliven, B. C., & Antel, J. P. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.080478 · Cited by 96
Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects
Kovarik, J. M., Schmouder, R., Barilla, D., Rivière, G., Wang, Y., & Hunt, T. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004264165 · Cited by 95
Rao, T. S., Lariosa-Willingham, K. D., Lin, F., Palfreyman, E. L., Yu, N., Chun, J. J. M., & Webb, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03527-3 · Cited by 94
Self-citationSinger, I. I., Tian, M., Wickham, L. A., Lin, J. J., Matheravidathu, S. S., Forrest, M. J., MANDALA, S. M., & Quackenbush, E. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7151 · Cited by 92
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
Brinkmann, V., Chen, S., Feng, L., Pinschewer, D. D., Nikolova, Z. G., & Hof, R. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02126-6 · Cited by 90
Kume, H., Takeda, N., Oguma, T., Ito, S., Kondo, M., Ito, Y., & Shimokata, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110718 · Cited by 86
FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs
Hofmann, M., Brinkmann, V., & Zerwes, H. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.07.030 · Cited by 83
Single‐dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects
Kovarik, J. M., Schmouder, R., Barilla, D., Wang, Y., & Kraus, G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02065.x · Cited by 81
Pulmonary and vascular pharmacology of sphingosine 1-phosphate
Brinkmann, V., & Baumruker, T. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.12.004 · Cited by 71
Saini, H. S., Coelho, R. P., Goparaju, S. K., Jolly, P. S., Maceyka, M. W., Spiegel, S., & Sato‐Bigbee, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03451.x · Cited by 69
Sato, K., Tomura, H., Igarashi, Y., Ui, M., & Okajima, F. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7666 · Cited by 69
Sato, K., Ishikawa, K., Ui, M., & Okajima, F. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00279-x · Cited by 68
Papadopoulos, D., Rundle, J., Patel, R., Marshall, I. C. B., Stretton, J. L., Eaton, R., Richardson, J. C., Gonzalez, M., Philpott, K. L., & Reynolds, R. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22196 · Cited by 60
Lin, C., Chen, C., Lin, P., & Lee, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.043 · Cited by 57
Kovarik, J. M., Hartmann, S., Bartlett, M., Rivière, G., Neddermann, D., Wang, Y., Port, A., & Schmouder, R. (2007) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.535 · Cited by 50
Linking Chinese medicine and G-protein-coupled receptors
Im, D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00012-3 · Cited by 45
MALCHINKHUU, E., SATO, K., MURAKI, T., ISHIKAWA, K., KUWABARA, A., & OKAJIMA, F. (2003) · Biochemical Journal · doi:10.1042/bj20020867 · Cited by 45
Böhler, T., Waiser, J., Schuetz, M., Neumayer, H., & Budde, K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg599 · Cited by 42
Zhang, Z., Zhang, Z., Fauser, U., Artelt, M., Burnet, M. W. M., & Schluesener, H. J. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00019.x · Cited by 41
Pfaff, M., Powaga, N., Akinci, S., Schütz, W., Banno, Y., Wiegand, S., Kummer, W., Wess, J., & Haberberger, R. V. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-48 · Cited by 39
Zhang, J., Zhang, A., Sun, Y. L., Cao, X., & Zhang, N. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.295 · Cited by 31
Rao, T. S., Lariosa-Willingham, K. D., Lin, F., Yu, N., Tham, C., Chun, J. J. M., & Webb, M. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.03.005 · Cited by 31
Self-citationNeuroprotection and neuroregeneration in multiple sclerosis
Stangel, M. (2008) · Journal of Neurology · doi:10.1007/s00415-008-6014-x · Cited by 28
Cited by
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Cyster, J. G., & Schwab, S. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075011 · Cited by 815
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
An update on the biology of sphingosine 1-phosphate receptors
Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516
Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets
Tschoe, C., Bushnell, C. D., Duncan, P. W., Alexander-Miller, M. A., & Wolfe, S. Q. (2020) · Journal of Stroke · doi:10.5853/jos.2019.02236 · Cited by 490
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Metadata
- Authors
- Cohen, J. A., & Chun, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 69
- Issue
- 5
- Pages
- 759-777
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2160209245
- Cited by
- 393
- References
- 120
- FWCI
- 24.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.